Ipiaconitine enteric-coated preparation

Abstract

The invention discloses an ipiaconitine enteric-coated preparation. The raw materials of the preparation comprise, by weight, 15 to 20 parts of ipiaconitine raw material medicine, 1.5 to 2 parts of dextrin, 1 to 1.5 parts of calcium sulfate, 1.8 to 2 parts of starch, 0.1 to 0.5 part of talcum powder, 2 to 2.5 parts of starch slurry, 4 to 5.3 parts of croscarmellose sodium, 0.5 to 1 part of acrylicresin type I, 0.5 to 1 part of acrylic resin type II, 12 to 15 parts of an ethanol solution, 0.2 to 0.4 part of propylene glycol, 0.3 to 0.5 part of castor oil, 0.1 to 0.5 part of magnesium stearateand 0.03 to 0.05 part of Chinese wax. The ipiaconitine raw material medicine is produced through chemical synthesis and high performance liquid chromatography separation and refining processes. The ipiaconitine enteric-coated preparation is stable in biological activity, simple in pilot plant test process, low in cost, free of disintegration when being eroded by gastric juice, rapid in disintegration when being eroded by intestinal juice, convenient for absorption of effective substances, high in stability, capable of being stored for a long time, common in raw materials and suitable for large-scale production.

Description

technical field [0001] The invention belongs to the field of enteric-coated preparations, and in particular relates to an ipiwutide enteric-coated preparation. Background technique [0002] Inflammation is a defense reaction of the body to stimulation, manifested as redness, swelling, heat, pain and dysfunction. Inflammation can be infectious inflammation caused by infection, or non-infectious inflammation not caused by infection. Usually, Inflammation is beneficial and is an automatic defense response of the human body, but sometimes, inflammation is also harmful, such as attacks on the body's own tissues, inflammation in transparent tissues, etc., so the emergence of anti-inflammatory drugs inhibits this phenomenon , the commonly used anti-inflammatory drugs are mostly oral medicines, and the effective substances in some oral medicines may cause damage to the gastric mucosa. Preparations, enteric-coated preparations can avoid this problem; [0003] Chinese patent CN10195...

AI Technical Summary

Problems solved by technology

[0004] The purpose of the present invention is to provide a kind of ipiwutide enteric-coated preparation, improve the defects of common enteric-coated preparations in the market at present, and synthesize a kind of ipiwutide raw material drug in the process of preparing the enteric-coated preparation. The raw material drug is produced through chemical synthesis and high-performance liquid chromatography separation and refining process. The biological activity is stable, the pilot test process is simple, and the cost is low. And the enteric-coated preparation of ipiutide will not disintegrate when it is eroded by gastric juice, and it will not disintegrate when it is eroded by intestinal juice. It disintegrates quickly when it is eroded, which is convenient for the absorption of effective substances. At the same time, the preparation has high stability and can be stored for a long time. The raw materials are common and suitable for large-scale production

Images